Explore Research Materials The peptide industry was shaken recently when Eli Lilly filed lawsuits against several companies accused of selling products purported to contain Retatrutide, the company's highly anticipated investigational obesity and diabetes drug. Retatrutide has generated significant attention because of promising clinical trial results, but it has not yet received FDA approval for human use. According to Lilly, the lawsuits target companies that are allegedly